Comparison of alternate-day versus consecutive-day treatment with S-1: Assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo

International Journal of Clinical Oncology

Volumn 13, Issue 6, 2008, Pages 515-520

  Arai, Wataru ^a   Hosoya, Yoshinori ^a   Haruta, Hidenori ^a   Kurashina, Kentaro ^a   Saito, Shin ^a   Hirashima, Yuuki ^a   Yokoyama, Taku ^a   Zuiki, Toru ^a   Sakuma, Kazuya ^a   Hyodo, Masanobu ^a   Yasuda, Yoshikazu ^a   Nagai, Hideo ^a   Shirasaka, Tetsuhiko ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Alternate day treatment with S 1; S 1; Toxic effects

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BONE MARROW DISEASES; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GASTROINTESTINAL TRACT; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TETRAZOLIUM SALTS; TUMOR CELLS, CULTURED;

EID: 57849165882     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0780-4     Document Type: Article

References (26)

1. T. Shirasaka Y. Shimamoto H. Ohshimo 1996 Development of a novel form of 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557
2. T. Shiraska S. Yamamitsu A. Tsuji 2000 Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidene prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan Invest New Drugs 18 315 329
3. K. Tatsumi M. Fukushima T. Shirasaka 1987 Inhibitory effects of pyrimidine, barbituric acid and pyrimidine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748 755
4. T. Shirasaka Y. Shimamoto M. Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009
5. Y. Sakata A. Ohtsu N. Horikoshi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
6. W. Koizumi M. Kurihara S. Nakano 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197
7. Y. Maehara 2003 S-1 in gastric cancer: a comprehensive review Gastric Cancer 6 Suppl1 2 8
8. F. Nagashima A. Ohtsu S. Yoshida 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6 11
9. Y. Maehara K. Sugimachi M. Kurihara 1999 Clinical effect of novel oral fluoropyrimidine anticancer drug TS-1 capsule in advanced gastrointestinal cancer patients (in Japanese) Hematology & Oncology 38 468 475
10. W. Arai Y. Hosoya M. Hyodo 2002 Every-other-day TS-1 administration for recurrent or non-curative advanced gastric carcinoma (in Japanese) Gan To Kagaku Ryoho 29 1651 1655
11. W. Arai Y. Hosoya M. Hyodo 2004 Alternate-day oral therapy with TS-1 for advanced gastric cancer Int J Clin Oncol 9 143 148
12. W. Arai Y. Hosoya T. Yokoyama 2004 A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1 (in Japanese) Gan To Kagaku Ryoho 31 237 240
13. A.A. Ovejera D.P. Houchens A.D. Barker 1978 Chemotherapy of human tumor xenografts in genetically athymic mice Ann Clin Lab Sci 8 50 56
14. M. Lipkin P. Sherlock B. Bell 1963 Cell proliferation kinetics in the gastrointestinal tract of man II cell renewal stomach, ileum, colon, and rectum Gastroenterology 45 721 729
15. B. Clarkson K. Ota T. Ohkita 1965 Kinetics of proliferation of cancer cells in neoplastic effusions in man Cancer 18 1189 1213
16. T. Shirasaka 2000 Conceptual changes in cancer chemotherapy. Biochemical modulation of 5-FU from bench to clinic Jpn J Cancer Chemother 27 SupplII 193 205
17. H. Hojo 1977 Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics (in Japanese) Niigata Med J 91 736 752
18. N. Katayanagi 1990 An experimental study of anticancer agent sensitivity test in human gastric cancer cell lines by flow cytometry (in Japanese) Nippon Geka Gakkai Zasshi 91 827 836
19. Y. Iwatani T. Kamigaki S. Suzuki 1999 Proliferating cell nuclear antigen as a predictor of therapeutic effect of continuous 5-fluorouracil administration in gastric cancer Int J Oncol 14 965 970
20. H. Fujiwara M. Terashima T. Irinoda 2003 Superior antitumor activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity Eur J Cancer 39 2387 2394
21. M. Fukushima H. Satake J. Uchida 1998 Preclinical antitumor efficacy of S-1:a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693 698
22. M. Terashima H. Fujiwara A. Takagane 2003 Prediction of sensitivity for fluoropyrimidines by metabolic and target enzyme activities in gastric cancer Gastric Cancer 6 71 81
23. M. Fukushima Y. Shimamoto T. Kato 1998 Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil Anticancer Drugs 9 817 823
24. M. Suzuki I. Sekguchi I. Sato 1996 Combined effects of S-1, a new form of oral Tegafur, plus modulators on ovarian cancer in nude rats Chemotherapy 42 452 458
25. K. Ikeda H. Masuda K. Yoshisue 1997 Disposition of components of new anti-cancer drug S-1(8): species differences, dose proportionality (in Japanese) Xenobio Metabol and Dispos 12 656 667
26. S. Sakuramoto M. Sasako T. Yamaguchi 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820